Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock
Portfolio Pulse from Vandana Singh
Reviva Pharmaceuticals Holdings Inc (RVPH) shares surged after the company released positive results from its Phase 3 RECOVER trial for brilaroxazine, a drug for adults with schizophrenia. The trial met its primary endpoint, with a significant reduction in PANSS total score. Roth Capital Partners maintains a Buy rating for RVPH with a price target of $12, noting robust data across multiple endpoints. However, they also noted a higher than expected weight gain in patients, which will be further evaluated.
October 30, 2023 | 5:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reviva Pharmaceuticals' positive Phase 3 trial results for its schizophrenia drug have led to a surge in its stock price. Roth Capital maintains a Buy rating with a price target of $12.
The positive results from the Phase 3 trial of Reviva Pharmaceuticals' schizophrenia drug have led to a surge in its stock price. This is a significant development for the company, and the maintained Buy rating from Roth Capital, along with a price target of $12, indicates strong confidence in the company's prospects. However, the noted higher than expected weight gain in patients could potentially impact the drug's market acceptance and should be monitored closely.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100